

AMENDED IN SENATE APRIL 3, 2008

SENATE BILL

No. 1504

Introduced by Senator Ridley-Thomas

February 21, 2008

An act to amend Sections 4052.5 and 4073 of the Business and Professions Code, relating to pharmacies.

LEGISLATIVE COUNSEL'S DIGEST

SB 1504, as amended, Ridley-Thomas. Antiepileptic drug products: substitution.

Existing law, the Pharmacy Law, provides for the licensure and regulation of pharmacists by the California State Board of Pharmacy, and makes a knowing violation of the act a crime. Existing law authorizes a pharmacist filling a prescription order for a drug product prescribed by its trade or brand name to substitute a generic drug product, subject to specified requirements. Existing law authorizes a pharmacist filling a prescription order for a drug product to substitute a drug product with a different form of medication having the same active chemical ingredients of equivalent strength and duration of therapy as the prescribed drug product, subject to specified requirements.

This bill would prohibit a pharmacist filling a prescription order for an antiepileptic drug or formulation of an antiepileptic drug, prescribed by its trade, brand, or generic name for the treatment or prevention of epileptic seizures, from substituting a drug product pursuant to those provisions without prior notification of the prescriber and the signed consent of the patient or the patient's parent, legal guardian, or spouse.

Because this bill would impose a new prohibition under the Pharmacy Law, the violation of which would be a crime, it would impose a state-mandated local program.

The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.

This bill would provide that no reimbursement is required by this act for a specified reason.

Vote: majority. Appropriation: no. Fiscal committee: yes.

State-mandated local program: yes.

The people of the State of California do enact as follows:

1 SECTION 1. Section 4052.5 of the Business and Professions
2 Code is amended to read:

3 4052.5. (a) In addition to the authority allowed under Section
4 4073, but subject to the express prohibition set forth in subdivision
5 (f) of Section 4073, a pharmacist filling a prescription order for a
6 drug product may select a different form of medication with the
7 same active chemical ingredients of equivalent strength and
8 duration of therapy as the prescribed drug product when the change
9 will improve the ability of the patient to comply with the prescribed
10 drug therapy.

11 (b) In no case shall a selection be made pursuant to this section
12 if the prescriber personally indicates, either orally or in his or her
13 own handwriting, "Do not substitute" or words of similar meaning.
14 Nothing in this subdivision shall prohibit a prescriber from
15 checking a box on a prescription marked "Do not substitute" if the
16 prescriber personally initials the box or checkmark.

17 (c) Selection pursuant to this section is within the discretion of
18 the pharmacist, except as provided in subdivision (b). The
19 pharmacist who selects the drug product to be dispensed pursuant
20 to this section shall assume the same responsibility for selecting
21 the dispensed drug product as would be incurred in filling a
22 prescription for a drug product using the prescribed form of
23 medication. There shall be no liability on the prescriber for an act
24 or omission by a pharmacist in selecting, preparing, or dispensing
25 a drug product pursuant to this section.

26 (d) This section shall apply to all prescriptions, including those
27 presented by or on behalf of persons receiving assistance from the
28 federal government or pursuant to the California Medical
29 Assistance Program set forth in Chapter 7 (commencing with

1 Section 14000) of Part 3 of Division 9 of the Welfare and
2 Institutions Code.

3 (e) When a substitution is made pursuant to this section, the use
4 of the different form of medication shall be communicated to the
5 patient, and the name of the dispensed drug product shall be
6 indicated on the prescription label, unless the prescriber orders
7 otherwise.

8 (f) This section shall not permit substitution between long-acting
9 and short-acting forms of a medication with the same chemical
10 ingredients or between one drug product and two or more drug
11 products with the same chemical ingredients.

12 SEC. 2. Section 4073 of the Business and Professions Code is
13 amended to read:

14 4073. (a) A pharmacist filling a prescription order for a drug
15 product prescribed by its trade or brand name may select another
16 drug product with the same active chemical ingredients of the same
17 strength, quantity, and dosage form, and of the same generic drug
18 name as determined by the United States Adopted Names (USAN)
19 and accepted by the federal Food and Drug Administration (FDA),
20 of those drug products having the same active chemical ingredients.

21 (b) In no case shall a selection be made pursuant to this section
22 if the prescriber personally indicates, either orally or in his or her
23 own handwriting, "Do not substitute," or words of similar meaning.
24 Nothing in this subdivision shall prohibit a prescriber from
25 checking a box on a prescription marked "Do not substitute";
26 provided that the prescriber personally initials the box or
27 checkmark. To indicate that a selection shall not be made pursuant
28 to this section for an electronic data transmission prescription as
29 defined in subdivision (c) of Section 4040, a prescriber may
30 indicate "Do not substitute," or words of similar meaning, in the
31 prescription as transmitted by electronic data, or may check a box
32 marked on the prescription "Do not substitute." In either instance,
33 it shall not be required that the prohibition on substitution be
34 manually initialed by the prescriber.

35 (c) Selection pursuant to this section is within the discretion of
36 the pharmacist, except as provided in subdivisions (b) and (f). The
37 person who selects the drug product to be dispensed pursuant to
38 this section shall assume the same responsibility for selecting the
39 dispensed drug product as would be incurred in filling a
40 prescription for a drug product prescribed by generic name. There

1 shall be no liability on the prescriber for an act or omission by a
 2 pharmacist in selecting, preparing, or dispensing a drug product
 3 pursuant to this section. In no case shall the pharmacist select a
 4 drug product pursuant to this section unless the drug product
 5 selected costs the patient less than the prescribed drug product.
 6 Cost, as used in this subdivision, is defined to include any
 7 professional fee that may be charged by the pharmacist.

8 (d) This section shall apply to all prescriptions, including those
 9 presented by or on behalf of persons receiving assistance from the
 10 federal government or pursuant to the California Medical
 11 Assistance Program set forth in Chapter 7 (commencing with
 12 Section 14000) of Part 3 of Division 9 of the Welfare and
 13 Institutions Code.

14 (e) When a substitution is made pursuant to this section, the use
 15 of the cost-saving drug product dispensed shall be communicated
 16 to the patient and the name of the dispensed drug product shall be
 17 indicated on the prescription label, except where the prescriber
 18 orders otherwise.

19 (f) In no case shall a pharmacist filling a prescription order for
 20 an antiepileptic drug, or formulation of an antiepileptic drug
 21 prescribed by its trade, brand, or generic name for the treatment
 22 or prevention of epileptic seizures, substitute a drug product
 23 pursuant to this section or subdivision (a) of Section 4052.5 without
 24 prior notification of the prescriber and the signed consent to the
 25 substitution from the patient or the patient’s parent, legal guardian,
 26 or spouse.

27 For purposes of this subdivision, the following definitions apply:

28 (1) “Antiepileptic drug” means any drug approved by the United
 29 States Food and Drug Administration (FDA) for the treatment of
 30 epilepsy or the treatment or prevention of epileptic seizures.

31 (2) “Epilepsy” means a neurological condition characterized by
 32 recurrent seizures.

33 (3) “Seizure” means an acute clinical change secondary to a
 34 brief disturbance in the electrical activity of the brain.

35 (4) ~~“Substitute”~~ “Select,” “selection,” “substitute,” or
 36 “substitution” means the substitution for an antiepileptic drug
 37 originally prescribed ~~of a~~ *with any other* version of the same
 38 antiepileptic drug, ~~including a generic version for the prescribed~~
 39 ~~generic version, a generic version by one manufacturer for a generic~~
 40 ~~version by a different manufacturer, or a different formulation of~~

1 ~~the prescribed antiepileptic drug; antiepileptic drug, including, but~~
2 ~~not limited to, any of the following:~~

3 (A) A generic version for the prescribed trade or brand name
4 drug.

5 (B) A trade or brand name drug for the prescribed generic
6 version.

7 (C) A generic drug produced by one manufacturer for a generic
8 drug produced by a different manufacturer.

9 (D) Any dosage form of that prescribed antiepileptic drug that
10 differs from the dosage form originally prescribed by the
11 prescriber.

12 SEC. 3. No reimbursement is required by this act pursuant to
13 Section 6 of Article XIII B of the California Constitution because
14 the only costs that may be incurred by a local agency or school
15 district will be incurred because this act creates a new crime or
16 infraction, eliminates a crime or infraction, or changes the penalty
17 for a crime or infraction, within the meaning of Section 17556 of
18 the Government Code, or changes the definition of a crime within
19 the meaning of Section 6 of Article XIII B of the California
20 Constitution.